19 August 2026, 05:34 PM
Submitting a connected medical device to the FDA involves more than attaching a few cybersecurity reports to your application. You need to show how your team identified security risks, tested the device, applied controls, and planned to manage vulnerabilities after release.
This level of evidence matters because weaknesses in connected devices can lead to serious consequences. An academic review of FDA safety communications found that 94% of the reported medical device cybersecurity vulnerabilities were classified as high severity. These weaknesses could allow remote access, code execution, or disruption of device functions.
Given the potential impact, manufacturers need to understand what the FDA actually expects. FDA cybersecurity documentation is not a fixed package of 14 or 20 separate files. Section 524B defines binding requirements for qualifying cyber devices, while FDA guidance explains the evidence needed to support those requirements.
This article will help you prepare that evidence, connect related records, and present them clearly for FDA review.
Key Takeaways
Section 524B creates binding FDA cybersecurity requirements for qualifying cyber devices. FDA guidance provides nonbinding recommendations, while voluntary standards can support the evidence submitted.
Manufacturers must provide a postmarket vulnerability plan, cybersecurity processes, update and patch procedures, and an SBOM covering commercial, open source, and off-the-shelf software.
The FDA reviews the complete evidence package to determine reasonable assurance of cybersecurity. One report, certificate, or standard alone is not enough. Cybersecurity must also connect with design controls, risk management, supplier controls, software validation, CAPA, and postmarket activities.
Source: https://qualysec.com/fda-cybersecurity-documentation-guidance/
This level of evidence matters because weaknesses in connected devices can lead to serious consequences. An academic review of FDA safety communications found that 94% of the reported medical device cybersecurity vulnerabilities were classified as high severity. These weaknesses could allow remote access, code execution, or disruption of device functions.
Given the potential impact, manufacturers need to understand what the FDA actually expects. FDA cybersecurity documentation is not a fixed package of 14 or 20 separate files. Section 524B defines binding requirements for qualifying cyber devices, while FDA guidance explains the evidence needed to support those requirements.
This article will help you prepare that evidence, connect related records, and present them clearly for FDA review.
Key Takeaways
- Not every connected product falls under Section 524B. The law applies only when all three parts of the FDA cyber device definition are met.
- For a covered device, manufacturers need to account for software components and show how vulnerabilities, disclosures, patches, and updates will be managed after release.
- FDA is more concerned with the quality of the evidence than the number of separate files included in the submission.
- Penetration testing is valuable when it confirms real attack paths and verifies fixes. It still forms only one part of a wider process that includes secure development, risk management, and lifecycle planning.
Section 524B creates binding FDA cybersecurity requirements for qualifying cyber devices. FDA guidance provides nonbinding recommendations, while voluntary standards can support the evidence submitted.
Manufacturers must provide a postmarket vulnerability plan, cybersecurity processes, update and patch procedures, and an SBOM covering commercial, open source, and off-the-shelf software.
The FDA reviews the complete evidence package to determine reasonable assurance of cybersecurity. One report, certificate, or standard alone is not enough. Cybersecurity must also connect with design controls, risk management, supplier controls, software validation, CAPA, and postmarket activities.
Source: https://qualysec.com/fda-cybersecurity-documentation-guidance/